Header

UZH-Logo

Maintenance Infos

About ATMPs, SOPs and GMP: the hurdles to produce novel skin grafts for clinical use


Hartmann-Fritsch, Fabienne; Marino, Daniela; Reichmann, Ernst (2016). About ATMPs, SOPs and GMP: the hurdles to produce novel skin grafts for clinical use. Transfusion Medicine and Hemotherapy, 43(5):344-352.

Abstract

BACKGROUND: The treatment of severe full-thickness skin defects represents a significant and common clinical problem worldwide. A bio-engineered autologous skin substitute would significantly reduce the problems observed with today's gold standard.
METHODS: Within 15 years of research, the Tissue Biology Research Unit of the University Children's Hospital Zurich has developed autologous tissue-engineered skin grafts based on collagen type I hydrogels. Those products are considered as advanced therapy medicinal products (ATMPs) and are routinely produced for clinical trials in a clean room facility following the guidelines for good manufacturing practice (GMP). This article focuses on hurdles observed for the translation of ATMPs from research into the GMP environment and clinical application.
RESULTS AND CONCLUSION: Personalized medicine in the field of rare diseases has great potential. However, ATMPs are mainly developed and promoted by academia, hospitals, and small companies, which face many obstacles such as high financial burdens.

Abstract

BACKGROUND: The treatment of severe full-thickness skin defects represents a significant and common clinical problem worldwide. A bio-engineered autologous skin substitute would significantly reduce the problems observed with today's gold standard.
METHODS: Within 15 years of research, the Tissue Biology Research Unit of the University Children's Hospital Zurich has developed autologous tissue-engineered skin grafts based on collagen type I hydrogels. Those products are considered as advanced therapy medicinal products (ATMPs) and are routinely produced for clinical trials in a clean room facility following the guidelines for good manufacturing practice (GMP). This article focuses on hurdles observed for the translation of ATMPs from research into the GMP environment and clinical application.
RESULTS AND CONCLUSION: Personalized medicine in the field of rare diseases has great potential. However, ATMPs are mainly developed and promoted by academia, hospitals, and small companies, which face many obstacles such as high financial burdens.

Statistics

Citations

Dimensions.ai Metrics
5 citations in Web of Science®
5 citations in Scopus®
3 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

18 downloads since deposited on 12 Jan 2017
13 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Children's Hospital Zurich > Clinic for Surgery
Dewey Decimal Classification:610 Medicine & health
Language:German
Date:September 2016
Deposited On:12 Jan 2017 15:30
Last Modified:22 Apr 2018 07:15
Publisher:Karger
ISSN:1660-3796
OA Status:Green
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.1159/000447645
PubMed ID:27781022
Project Information:
  • : FunderFP7
  • : Grant ID279024
  • : Project TitleEUROSKINGRAFT - A novel generation of skin substitutes to clinically treat a broad spectrum of severe skin defects
  • : FunderFP7
  • : Grant ID238551
  • : Project TitleMULTITERM - Training Multidisciplinary scientists for Tissue Engineering and Regenerative Medicine
  • : FunderFP7
  • : Grant ID607868
  • : Project TitleITERM - Training scientists to develop and Image materials for Tissue Engineering and Regenerative Medicine

Download

Download PDF  'About ATMPs, SOPs and GMP: the hurdles to produce novel skin grafts for clinical use'.
Preview
Content: Published Version
Filetype: PDF
Size: 440kB
View at publisher